Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and electroCore (NASDAQ:ECOR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Anteris Technologies Global and electroCore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -4,619.27% | -77.69% | -67.99% |
| electroCore | -39.96% | -1,956.38% | -81.35% |
Risk & Volatility
Anteris Technologies Global has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
Anteris Technologies Global currently has a consensus target price of $16.00, suggesting a potential upside of 105.92%. electroCore has a consensus target price of $18.00, suggesting a potential upside of 64.84%. Given Anteris Technologies Global’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than electroCore.
Institutional & Insider Ownership
26.7% of electroCore shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by insiders. Comparatively, 7.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Anteris Technologies Global and electroCore”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $2.24 million | 337.76 | -$94.14 million | ($1.95) | -3.98 |
| electroCore | $32.03 million | 3.08 | -$13.97 million | ($1.66) | -6.58 |
electroCore has higher revenue and earnings than Anteris Technologies Global. electroCore is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Summary
Anteris Technologies Global beats electroCore on 8 of the 14 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
